Subtopic Deep Dive

Galectins in Angiogenesis
Research Guide

What is Galectins in Angiogenesis?

Galectins in angiogenesis refers to the role of galectin proteins, particularly galectin-3 and galectin-1, in promoting endothelial cell morphogenesis, VEGF signaling, and vascular remodeling during tumor angiogenesis. (Croci et al., 2014; Nangia-Makker et al., 2000)

Galectins drive angiogenesis by binding glycosylated receptors on endothelial cells, enhancing migration and tube formation. Galectin-3 mediates VEGF- and bFGF-induced angiogenic responses (Markowska et al., 2010, 320 citations). Glycosylation-dependent galectin interactions sustain angiogenesis in anti-VEGF refractory tumors (Croci et al., 2014, 487 citations). Over 10 papers from the list address galectin mechanisms in vascularization.

Curated Papers

Key Challenges

Why It Matters

Galectin-driven angiogenesis supports tumor vascularization, enabling growth and metastasis; blocking galectin-1 preserves anti-VEGF efficacy in refractory tumors (Croci et al., 2014). Galectin-3 induces endothelial morphogenesis, promoting pathological angiogenesis in cancer (Nangia-Makker et al., 2000). Targeting galectin-glycosylation interactions offers therapies for tumors resistant to VEGF inhibitors, impacting wound healing and inflammatory vascular diseases (Markowska et al., 2010; Stowell et al., 2015). Aberrant glycosylation by galectins alters tumor microenvironments to favor vessel formation (Peixoto et al., 2019).

Key Research Challenges

Galectin-VEGF Resistance

Tumors evade anti-VEGF therapy via galectin-lectin interactions that sustain angiogenesis (Croci et al., 2014). Developing inhibitors requires understanding glycosylation dependencies. Clinical translation faces specificity issues in endothelial targeting.

Galectin Isoform Specificity

Galectin-3 promotes VEGF/bFGF responses, but isoform roles in different cancers vary (Markowska et al., 2010; Nangia-Makker et al., 2000). Selective inhibitors risk off-target effects on normal vessels. Quantifying isoform contributions in vivo remains challenging.

Glycosylation Heterogeneity

Cancer glycosylation alters galectin binding, driving angiogenesis hallmarks (Munkley and Elliott, 2016; Peixoto et al., 2019). Mapping patient-specific glycan profiles for therapy is technically demanding. Integrating glycomics with angiogenesis assays needs standardization.

Essential Papers

Protein Glycosylation in Cancer

Sean R. Stowell, Tongzhong Ju, Richard D. Cummings · 2015 · Annual Review of Pathology Mechanisms of Disease · 861 citations

Neoplastic transformation results in a wide variety of cellular alterations that impact the growth, survival, and general behavior of affected tissue. Although genetic alterations underpin the deve...

Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer

Deok-Hoon Kong, Young Kim, Mi Kyung Kim et al. · 2018 · International Journal of Molecular Sciences · 661 citations

Tumor necrosis factor alpha (TNFα) is a pro-inflammatory cytokine that triggers the expression of inflammatory molecules, including other cytokines and cell adhesion molecules. TNFα induces the exp...

Chitinase-3 like-protein-1 function and its role in diseases

Ting Zhao, Zhongping Su, Yingchang Li et al. · 2020 · Signal Transduction and Targeted Therapy · 535 citations

Abstract Non-enzymatic chitinase-3 like-protein-1 (CHI3L1) belongs to glycoside hydrolase family 18. It binds to chitin, heparin, and hyaluronic acid, and is regulated by extracellular matrix chang...

Hallmarks of glycosylation in cancer

Jennifer Munkley, David J. Elliott · 2016 · Oncotarget · 488 citations

Aberrant glycosylation plays a fundamental role in key pathological steps of tumour development and progression. Glycans have roles in cancer cell signalling, tumour cell dissociation and invasion,...

Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors

Diego O. Croci, Juan P. Cerliani, Tomás Dalotto‐Moreno et al. · 2014 · Cell · 487 citations

Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis

Pratima Nangia‐Makker, Yuichiro Honjo, Rebecca Sarvis et al. · 2000 · American Journal Of Pathology · 442 citations

Increasing evidence suggests that carbohydrate-binding proteins play an essential role in tumor growth and metastasis. However, conflicting results on their function in the regulation of cell proli...

The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review

Wentao Ma, Fei Gao, Kui Gu et al. · 2019 · Frontiers in Immunology · 347 citations

Monocytes (Mo) and macrophages (Mϕ) are key components of the innate immune system and are involved in regulation of the initiation, development, and resolution of many inflammatory disorders. In a...

Reading Guide

Foundational Papers

Read Nangia-Makker et al. (2000) first for galectin-3 inducing endothelial morphogenesis (442 citations), then Markowska et al. (2010) for VEGF/bFGF mediation (320 citations), and Croci et al. (2014) for anti-VEGF resistance (487 citations) to build core mechanisms.

Recent Advances

Study Peixoto et al. (2019) for glycosylation-tumor microenvironment links and Munkley and Elliott (2016) for cancer glycosylation hallmarks driving angiogenesis.

Core Methods

Endothelial cell migration/tube formation assays (Nangia-Makker et al., 2000); VEGF stimulation with galectin knockout (Markowska et al., 2010); glycosylation-lectin binding in tumor models (Croci et al., 2014).

How PapersFlow Helps You Research Galectins in Angiogenesis

Discover & Search

PapersFlow's Research Agent uses searchPapers and exaSearch to find galectin angiogenesis papers like 'Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors' (Croci et al., 2014). citationGraph reveals connections from Nangia-Makker et al. (2000) to Markowska et al. (2010), while findSimilarPapers expands to glycosylation-cancer links.

Analyze & Verify

Analysis Agent applies readPaperContent to extract VEGF-galectin mechanisms from Croci et al. (2014), then verifyResponse with CoVe checks claims against Markowska et al. (2010). runPythonAnalysis performs statistical meta-analysis of citation impacts or angiogenesis assay data from abstracts; GRADE grading scores evidence strength for galectin-3's pro-angiogenic role.

Synthesize & Write

Synthesis Agent detects gaps in galectin isoform therapies via contradiction flagging across Croci (2014) and Nangia-Makker (2000); Writing Agent uses latexEditText, latexSyncCitations for review drafts, and latexCompile for publication-ready manuscripts with exportMermaid for VEGF signaling diagrams.

Use Cases

"Analyze galectin-3's role in VEGF-mediated angiogenesis from key papers"

Research Agent → searchPapers('galectin-3 VEGF angiogenesis') → Analysis Agent → readPaperContent(Markowska 2010) + runPythonAnalysis(pandas meta-analysis of endothelial assay data) → quantified pro-angiogenic effect sizes and p-values.

"Draft LaTeX review on galectins in anti-VEGF resistance"

Synthesis Agent → gap detection(Croci 2014 gaps) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile → camera-ready PDF with synced bibliography.

"Find code for galectin-endothelial migration simulations"

Research Agent → paperExtractUrls(galectin papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python scripts for angiogenesis modeling from related glycosylation repos.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers(50+ galectin angiogenesis papers) → citationGraph → DeepScan(7-step analysis with GRADE checkpoints) → structured report on isoform roles. Theorizer generates hypotheses like 'galectin-8 inhibitors enhance anti-VEGF in gliomas' from Croci (2014) + Markowska (2010) patterns. DeepScan verifies galectin-3 morphogenesis claims across Nangia-Makker (2000) with CoVe.

Try Doxa for Galectins in Angiogenesis Research

Frequently Asked Questions

What defines galectins in angiogenesis?

Galectins promote endothelial migration and VEGF signaling via glycan binding (Croci et al., 2014; Markowska et al., 2010). Galectin-3 induces tube formation (Nangia-Makker et al., 2000).

What methods study galectin angiogenesis?

Endothelial morphogenesis assays and VEGF/bFGF stimulation measure galectin effects (Nangia-Makker et al., 2000; Markowska et al., 2010). Glycosylation inhibition tests preserve anti-VEGF response (Croci et al., 2014).

What are key papers?

Croci et al. (2014, 487 citations) on lectin preservation of angiogenesis; Nangia-Makker et al. (2000, 442 citations) on galectin-3 morphogenesis; Markowska et al. (2010, 320 citations) on VEGF mediation.

What open problems exist?

Developing isoform-specific inhibitors without vascular toxicity. Mapping glycosylation heterogeneity in patient tumors. Integrating galectins into combination anti-angiogenic therapies (Croci et al., 2014; Peixoto et al., 2019).